• Home
  • About Us
  • Technology
  • Pipeline
  • Partnerships
  • News & Publications
HDT Bio

Replicating RNA platform enables rapid response to the SARS-CoV-2 Omicron variant and elicits enhanced protection in naïve hamsters compared to ancestral vaccine. — EBioMedicine

Sep 1, 2022 | Publications

Click here to view...

A replicon RNA vaccine induces durable protective immunity from SARS-CoV-2 in nonhuman primates after neutralizing antibodies have waned — BiorXiv

Aug 9, 2022 | Publications

Click here to view...

Replicating RNA vaccination elicits an unexpected immune response that efficiently protects mice against lethal Crimean-Congo hemorrhagic fever virus challenge. — EBioMedicine

Jul 27, 2022 | Publications

Click here to view...

Intramuscular delivery of formulated RNA encoding six linked nanobodies is highly protective for exposures to three Botulinum neurotoxin serotypes. — Nature Scientific Reports

Jul 8, 2022 | Publications

Click here to view...

Vaccine Researchers Face Unique Challenges in Updating New Covid Boosters

Apr 18, 2022 | Publications

Click here to view...
Next Entries »

Recent Posts

  • Providence Swedish Neuroscience Institute (PSNI) Reaches Milestone in Reducing Global Burden of Glioblastoma
  • A New Approach to Treating Brain Cancer: HDT Bio Launches Canadian Clinical Program at McGill University
  • KING5 Seattle Healthlink Feature: Seattle-based group testing new immunotherapy approach to treat deadly form of brain cancer
  • HDT Bio and UTMB Receive MCDC Innovation Prototype Award for Advancing CCHF Vaccine from Lab to Phase 1 Clinical Trial
  • FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease

Recent Comments

No comments to show.

Privacy Policy

Terms of Use

©2024 HDT Bio

  • Follow
  • Follow